SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING
REASON AREA DATE OF FOR OF SUBSTANCE ENTRY LISTING USE
4-[4-(ACETYLOXY)PHENYL]-2-
BUTANONE Feb 2005 b 1.7
AGROBACTERIUM RADIOBACTER Nov 1989 a 1
ALCOHOL, DEHYDRATED Aug 2000 b 6
ALUM May 1997 a 7.1
ALUMINIUM AMMONIUM SULFATE May 1997 a 7.1
ALUMINIUM POTASSIUM SULFATE May 1997 a 7.1
ALUMINIUM SILICATE Nov 1974 a 7.1
ALUMINIUM tris (ETHYLPHOSPHONATE) Aug 1986 a 1
AMETOCTRADIN May 2012 a 1.3
AMMONIUM PHOSPHATE Nov 1974 a 7.1
AMMONIUM THIOSULPHATE Nov 1974 a 7.1
AMPROLIUM Jun 1969 a 2.3
AMYL ACETATE Nov 1974 a 7.1
α -AMYLASE derived from Aspergillus niger Feb 2005 a 2.4
ANDROSTENEDIONE ALBUMEN
CONJUGATE WITH DEA DEXTRAN
ADJUNCT Jun 2004 a 2.1
ASPARTIC ACID - a 6
ASULAM May 1986 a 1
AZIMSULFURON Jun 2003 a 1.1
BACILLUS SPHAERICUS STRAIN 2362 Feb 2003 a 5.1
BACILLUS THURINGIENSIS May 1992 a 5.1 (excluding endotoxin) Jun 2003 a 2.10
BACILLUS TOYOI Aug 1980 a 2.9
BACULOVIRUS CYDIA POMONELLA Jun 2006 a 1.2
BENFLURALIN - a 1.1
BENSULFURON-METHYL Aug 1987 a 1
BENTONITE Jun 2002 a 7.1
BENZYL BENZOATE Aug 1989 a 1.3.4
BETAINE HYDROCHLORIDE Nov 1974 a 7.1
BIFENAZATE Oct 2002 a 1.9
BISMUTH SUBNITRATE Nov 1999 b, c 2.1
BISTRIFLURON Feb 2014 a 1.2.2
BIURET Nov 1974 a 2.4
BOSCALID June 2003 a 1.3
BOVINE SOMATOTROPHIN May 1992 a 2
BROMACIL Aug 1987 a 1
BROMOPROPYLATE Nov 1994 a 1
BUPIRIMATE Nov 1990 a 1
BUTAFENACIL May 2000 a 1
BUTOXYPOLYPROPYLENE GYLCOL Nov 1974 a 7.7
n-BUTYL BUTYRATE - a 7.1
n-BUTYL LACTATE - a 7.1
CARBETAMIDE Aug 1991 a 1
CARBOXIN Aug 1987 a 1
CARFENTRAZONE-ETHYL Aug 1998 a 1
CELLULASE derived from Aspergillus niger Feb 2005 a 2.4
CETYL ALCOHOL Nov 1974 a 7.1
CHAMOMILE OIL Feb 2000 a 3.1
CHINA CLAY Nov 1974 a 7.1
CHLORANTRANILIPROLE Sep 2008 a 1.2
CHLORFLUAZURON Oct 2005 a 1.2.2
CHLORFLURENOL Feb 1974 a 1.6
CHLORIDAZON May 1988 a 1
CHLOROXYLENOLS Feb 1975 a 7.8
CITRONELLA OIL Feb 2000 a 7.1
CLARY SAGE OIL Feb 2000 a 7.1
CLOPIDOL Nov 1974 d 2.3
COBALT NAPHTHENATE - d 7.1
COLOPHONY Feb 1997 b 7.4
CROSPOVIDONE Aug 1996 a 2
CULICINOMYCES CLAVOSPORUS Nov 1982 a 5.1
CYCLAMIC ACID Nov 1971 a 7.1
CYCLOHEXANE Nov 1974 a 7.7
CYCLOHEXANOL ACETATE - a 7.7
CYROMAZINE Nov 1980 a 2
DICLAZURIL Nov 2001 a 2.3
DIETHYL CARBONATE - a 7.1
DIFLUFENICAN Feb 1987 a 1
DIKEGULAC-SODIUM Mar 1980 a 1.6
DIMETHICONE a 7.1
DIMETHYL ETHER Nov 1988 d 4
DIPHENYLAMINE Feb 1988 a 1
DIPROPYLENE GLYCOL MONOMETHYL ETHER Nov 1987 a 4
DIURON Nov 1987 a 1
DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) Feb 1970 a 7.1
2,2-DPA Nov 1989 a 1
drometrizole trisiloxane Oct 2003 a 6.4
EPSIPRANTEL Nov 1991 a 2
ETHAMETSULFURON-METHYL Nov 2000 a 1.1
ETHOPABATE Jun 1969 d 2.3
ETHYL ACETATE Nov 1974 a 7.1
ETHYL ALCOHOL Nov 1974 a 7.1
ETHYLBUTYLACETYL- AMINOPROPRIONATE Aug 2000 a 3.4
ETHYL BUTYRATE - a 7.1
ETHYL LACTATE - a 7.1
ETOXAZOLE Oct 2003 a 1.2
EUBACTERIUM sp. strain DSM11798 Sep 2013 a 2.4
FENFURAM May 1977 a 1.3.1
FENHEXAMID Feb 1999 a 1
FENOXYCARB Feb 1988 a 1
FLUFENOXURON Feb 1997 a 1
FLUMETSULAM Feb 1992 a 1
FLUOMETURON Aug 1989 a 1
FLUTOLANIL Nov 2001 a 1.3
FLUROXYPYR May 1986 a, c 1
FORCHLORFENURON Feb 2005 a 1.6
FULLERS EARTH Nov 1974 a 7.1
FUNGAL PROTEASE derived from
Aspergillus niger Feb 2005 a 2.4
GERANIUM OIL Feb 2000 a 7.1
GIBBERELLIC ACID Nov 1974 a 1.6
-GLUCANASE derived from Aspergillus niger Feb 2005 a 2.4
HALAUXIFEN METHYL Oct 2014 a 1, 1.1
HEXAFLURON Nov 1988 a 1
HEXYL ACETATE - a 7.7
HEXYTHIAZOX Feb 1988 a 1
HUMAN OSTEOGENIC PROTEIN-1 (OP-1) Aug 2001 b 6.2
HYDROPRENE Feb 1988 a 1
HYDROXYPROPYL CELLULOSE Nov 1982 a 7.1
ICODEXTRIN Nov 2000 b 6
INDOLE-3-ACETIC ACID Feb 1985 b 1.6
ISOPRENE ALCOHOL - a 7.1
IPRODIONE Feb 1997 a 1
ISOSTEARYL ALCOHOL ETHOXYLATE Nov 1999 a 5.1
KAOLIN Nov 1974 a 7.1
KRESOXIM-METHYL Aug 1999 a 1
KUNZEA OIL Feb 2000 a 7.1
LAURIC ACID Oct 2005 a 7.1
LAURYL ALCOHOL (1-DODECANOL) Nov 1974 a 7.1
LAVANDIN OIL Feb 2000 a 7.1
LAVENDER OIL Feb 2000 a 7.1
LEAD METALLIC - a 7.1
LEMONGRASS OIL Feb 2000 a 7.1
LEPIDOPTEROUS SEX PHEROMONES Nov 1990 a 1
LIMONENE (DIPENTENE) Jun 2002 a 7.1
LINOLEIC ACID Oct 2005 a 7.1
LINSEED FATTY ACIDS Aug 1990 a 2.1
LINURON Feb 1990 a 1
LIQUORICE, DEGLYCYRRHISINISED May 1999 a 7.1
MALEIC HYDRAZIDE Nov 1992 a 1
MANGANESE DIOXIDE May 1999 b 1
MEGASPHAERA ELSDENII strain 41125 Sep 2013 a 2.4
MESOLSULFURON-METHYL Feb 2002 a 1.1
METARHIZIUM ANISOPLIAE Feb 2000 b 4.2
METARHIZIUM ANISOPLIAE Jun 2003 a 1.10
METHOPRENE Aug 1987 a 1
METHOXYFENOZIDE Nov 2000 a 1
METHYL ACETATE - a 7.7
METHYL BENZOQUATE Nov 1974 d 2.3
1-METHYLCYCLOPROPENE Jun 2003 a 1.6
METHYL p-HYDROXYBENZOATE Nov 1974 a 7.9
METSULFURONMETHYL Nov 1985 a 1.1
MYRISTIC ACID Oct 2005 a 7.1
NAPROPAMIDE Aug 1987 a 1
NAPTHYL ACETAMIDE Nov 1974 a 1.6
NEROLI OIL Feb 2000 a 7.1
NICARBAZIN Jun 1969 d 2.3
NISIN Jun 2003 a 3.2
NORFLURAZON Nov 1983 a 1.1
NOVALURON Nov 2000 a 1
Nuclear Polyhedrosis Virus of Helicoverpa armigera occlusion bodies Feb 2004 a 1.2
OCTYL ALCOHOLS Nov 1974 a 7.1
OLEIC ACID Oct 2005 a 7.1
ORANGE OIL, SWEET Aug 2000 a 7.1
OXABETRINIL Feb 1987 a 1
OXYFLUORFEN May 2001 a 1
PALMAROSA OIL Feb 2000 a 7.1
PALMITIC ACID Oct 2005 a 7.1
PATCHOULI OIL Feb 2000 a 7.1
PECTINASE derived from Aspergillus niger Feb 2005 a 2.4
PENCYCURON Aug 1994 a 1
PENTADECANOIC ACID Oct 2005 a 7.1
PEPPERMINT OIL Feb 2000 a 7.1
PHENMEDIPHAM May 1989 a 1.1
d-PHENOTHRIN Feb 1982 a 7.5, 1.2
PHYTASE Feb 1996 a 2.4
PICLORAM Aug 1987 a 1
PICOLINAFEN May 2000 a 1
PIMELIC ACID Oct 2005 a 7.1
PIPERONYL BUTOXIDE Aug 1991 a 7.5
POLOXALENE Nov 1974 a 7.1
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC) Nov 1997 a 4.1
POLYHEDROSIS VIRUS of Helico zea occlusion bodies Nov 1996 a 1
POLY (GNRF) OVALBUMIN Feb 1990 a 2
POLYSORBATE 20 May 2001 a 1
PORCINE SOMATOTROPHIN Nov 1991 c 2
potassium sorbate Oct 2004 a 1.3
POTASSIUM BICARBONATE Jun 2004 a 1
PROPYL ACETATES - a 7.1
PROPYLENE GLYCOL Nov 1974 a 7.1
2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER Nov 1987 a 4
PROTHIOCONAZOLE June 2005 a 1.3.1
PSEUDOMONAS FLUORESCENS May 1985 a 1.8
PYRIMETHANIL Feb 1996 a 1
PYRIPROXYFEN Aug 1994 a 1
QUASSIA Nov 1974 d 6, 2.1
QUINOXYFEN Nov 2001 a 1.3
ROSEMARY OIL Feb 2000 a 7.1
SAGE OIL (Spanish) Feb 2000 a 7.1
SANDALWOOD OIL Feb 2000 a 7.1
SEAWEED & UNFRACTIONED SEAWEED EXTRACTS Feb 1985 d 1.5
SIMAZINE Nov 1987 a 1.1
SODIUM BICARBONATE Jun 2004 a 1
sodium propionate Oct 2004 a 1.3
STERIC ACID Oct 2005 a 7.1
SUCRALFATE Aug 1982 a 6.8
SULESOMAB Jun 2002 b 6.1
SULFOSULFURON Feb 1998 a 1
SULPHATED POLYSACCHARIDES - a 7.1
TANNIC ACID Dec 1965 a 7.1
TANNIC ACID/BENZYL ALCOHOL PRODUCT Nov 1993 a 7.1
TERBACIL Aug 1987 a 1
THAUMATIN Nov 1990 a 3.2
THIDIAZURON Nov 1989 a 1
TRIASULFURON Feb 1988 a 1
TRICHODERMA HARZIANUM May 1996 a 1
(Z)-9-TRICOSENE Aug 1991 a 1
TRIETHYLENE GLYCOL Nov 1974 a 7.1
TRIFLOXYSULFURON Feb 2002 a 1.1
TRIFLURALIN Aug 1990 a 1
TRIFORINE Aug 1987 a 1
Ulocladium oudemansii Oct 2003 a 1.10
UREA Nov 1974 a 7.1
13C-UREA May 2001 a 6.1
VETIVER OIL Feb 2000 a 7.1
VINYL ETHER Nov 1987 b 6
VITAMIN K Jul 1963 a 6.9, 2.8
XANTHOPHYLL (lutein) Nov 1974 a 7.1
XYLANASE derived from Aspergillus niger Feb 2005 a 2.4
YLANG YLANG OIL Feb 2000 a 7.1
ZINC NAPHTHENATE - a 1.3
APPENDIX C
SUBSTANCES, OTHER THAN THOSE INCLUDED IN SCHEDULE 9,
OF SUCH DANGER TO HEALTH AS TO WARRANT
PROHIBITION OF SALE, SUPPLY AND USE
ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.
ACORUS CALAMUS (calamus) for human therapeutic use.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:
(a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;
(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
(b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.
ALLYLISOPROPYLACETYLUREA for therapeutic use.
AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.
AMYGDALIN for therapeutic use.
ANCHUSA OFFICINALIS for therapeutic use.
ARISTOLOCHIA spp. for therapeutic use.
ARISTOLOCHIC ACID(S) for human therapeutic use.
ASARUM spp. containing aristolochic acid(s) for human therapeutic use.
AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except ‘debitterised neem seed oil’.
BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.
BITHIONOL for human therapeutic use.
BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.
BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.
BUCLOSAMIDE for therapeutic use.
BUNIODYL SODIUM for therapeutic use.
1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.
CACALIA spp. for therapeutic use.
CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.
CINCHOPHEN and its derivatives for therapeutic use.
CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use except when being used solely for experimental purposes in humans and where such use:
(a) is in accordance with:
(i) an approval granted under paragraph 19(1)(b) of the Therapeutic Goods Act 1989, including any conditions specified in the notice of approval; and
(ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Therapeutic Goods Act 1989; and
(iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Therapeutic Goods Act 1989; or
(b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990.
COAL TAR for cosmetic use other than in therapeutic goods.
CONIUM MACULATUM (coniine) for therapeutic use.
COTARNINE for therapeutic use.
CROTALARIA spp. for therapeutic use.
CROTON TIGLIUM for therapeutic use.
CYNOGLOSSUM spp. for therapeutic use.
DIBUTYLPHTHALATE for cosmetic use.
DICOPHANE (DDT) for therapeutic use.
DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of diethylene glycol.
DIETHYLHEXYL PHTHALATE for cosmetic use.
DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5 per cent or less of diethylphthalate.
5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.
1,3-DIMETHYLAMYLAMINE (DMAA).
DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5 per cent or less of dimethylphthalate.
DULCIN for therapeutic use.
ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of ethylene glycol.
ETHYLHEXANEDIOL for human use.
EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.
FARFUGIUM JAPONICUM for therapeutic use.
FORMALDEHYDE (excluding its derivatives):
in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
HELIOTROPIUM spp. for therapeutic use.
HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.
JUNIPERUS SABINE [savin(e)] for therapeutic use.
LEAD COMPOUNDS in paints, tinters, inks or ink additives except in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.
LIGULARIA DENTATA for therapeutic use.
MELIA AZEDARACH including its extracts and derivatives.
METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.
METHYL METHACRYLATE for cosmetic use except in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.
OXYPHENISATIN for therapeutic use.
PARAFORMALDEHYDE (excluding its derivatives):
(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;
(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or
(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
PETASITES spp. for therapeutic use.
PHENYLENEDIAMINES in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.
POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.
PTERIDIUM spp. for therapeutic use.
PULMONARIA spp. for therapeutic use.
SAFROLE for internal therapeutic use except in preparations containing 0.1 per cent or less of safrole.
SENECIO spp. for therapeutic use.
SILICONES for injection or implantation except when included in Schedule 4.
SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.
SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use except when included in Schedule 5.
TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.
1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.
TRICHODESMA AFRICANA for therapeutic use.
TRIPARANOL for therapeutic use.
TUSSILAGO FARFARA for therapeutic use.
APPENDIX D
ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8
(The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)
1. Poisons available only from or on the prescription or order of an authorised medical practitioner.
CLOMIPHENE for human use.
CLOZAPINE for human use.
CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use.
CYCLOFENIL for human use.
DINOPROST for human use.
DINOPROSTONE for human use.
FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.
FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.
LUTEINISING HORMONE for human use.
NABIXIMOLS.
SODIUM OXYBATE for human use.
TERIPARATIDE for human use.
UROFOLLITROPIN (human follicle-stimulating hormone) for human use.
2. Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age:
(1) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(2) if the drug is -
(a) acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or
(b) bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.
ACITRETIN for human use.
BEXAROTENE for human use.
ETRETINATE for human use.
ISOTRETINOIN for human oral use.
THALIDOMIDE for human use.
3. Poisons available only from or on the prescription or order of a medical practitioner authorised or approved by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the Therapeutic Goods Act 1989.
DRONABINOL (delta-9-tetrahydrocannabinol).
4. Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:
(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.
LENALIDOMIDE.
TRETINOIN for human oral use.
5. Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).
ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.
ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.
BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8.
DARBEPOETIN.
DEXTROPROPOXYPHENE.
EPHEDRINE.
EPOETINS.
ERYTHROPOIETIN.
ERYTHROPOIETINS except when separately specified in this Appendix.
FOLLISTATIN.
GLUTETHIMIDE.
INSULIN-LIKE GROWTH FACTORS.
PERAMPANEL for human use.
PHENTERMINE.
SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4.
SOMATROPIN (human growth hormone).
6. Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:
(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
(b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.
AMBRISENTAN for human use.
BOSENTAN for human use.
SITAXENTAN for human use.
7. Poisons available only from or on the prescription or order of a dermatologist.
ALEFACEPT for human use.
APPENDIX E
FIRST AID INSTRUCTIONS FOR POISONS
(other than agricultural and veterinary chemicals (including pesticides) registered by the
Australian Pesticides and Veterinary Medicines Authority and medicines for human use
when compliant with the requirements of the Required Advisory Statements for Medicine Labels)
INTRODUCTION
Directions for First Aid Attention
Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this Appendix may be varied provided that the intent is not changed.
The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.
These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.
Modified First Aid Instruction on Primary Pack
Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:
(a) each immediate container must be labelled with first aid instructions appropriate for its contents; and
(b) the primary pack must be labelled with the statement:
FIRST AID: See inner packs.
Exempt Preparations
This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the Schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:
1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. calls must be logged and submitted for incorporation into the official collection of poisoning data.
APPENDIX E
STANDARD STATEMENTS
To be grouped together and prefaced with the words “FIRST AID” (see subparagraph 7(p) of this Standard).
Basic
A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).
Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
General
G1 Urgent hospital treatment is likely to be needed. (Note the words ‘at once’ to be added to instruction A).
G2 If swallowed, give activated charcoal if instructed. (Note the words ‘at once’ to be added to instruction A).
G3 If swallowed, do NOT induce vomiting.
G4 Immediately give a glass of water.
G5 Avoid giving milk or oils.
G6 If sprayed in mouth, rinse mouth with water.
Eyes
E1 If in eyes wash out immediately with water.
E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.
Respiratory system
R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.
Skin
S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.
S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).
Special Purpose
SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.
APPENDIX E
FIRST AID INSTRUCTIONS
Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the Introduction to this Appendix).
POISON STANDARD STATEMENTS
Acetic acid A,G3,E2,S1
Acetic anhydride A,G3,E2,S1
Acetone A,G3
Acrolein A,G1,G2,G3,E2,R2,S2
Alkaline salts A,G3,E2,S1
Amines for use as curing agents A,G3,E1,S1
4-Aminopyridine A,G1,G2,E1,S1
Ammonia
• 5 per cent or less A
• above 5 per cent A,G3,E1,R1,S1
Ammonium persulfate A,G3,E2
Ammonium thiocyanate A
Anhydrides, organic acid, for use as curing agents for epoxy resins A,G3,E1,S1
Aniline A,E2,R1,S1
Anise oil A,G3
Antimony chloride A,E2,S2
Antimony compounds, except antimony chloride A
Azadirachta indica (neem) including its extracts and derivatives when included in Schedule 6. A,E1
Barium salts, except barium sulfate A
Basil oil A,G3
Bay oil A,G3
Benzalkonium chloride
• when included in Schedule 5 A,G3,E2
Benzene A,G3,E1,R1,S1
1,2-Benzenediol (Catechol) A,E1,S1
Benzoyl peroxide
• above 20 per cent A,E2,S1
• above 10 per cent up to 20 per cent A,E1
• 10 per cent or less A
Bergamot oil A,G3
Bifluorides (including ammonium, potassium and sodium salts)
• when included in Schedule 5 A
Borax A
Boric acid A
Boron trifluoride
• when included in Schedule 5 A
Bromoform A,G3,E2,R1,S2
Brucine A,G1,G2,G3,R2
2-Butoxyethanol and its acetates A,E2,S1
Cadmium compounds A
Cajuput oil A,G3
Camphor A,G1,G3,G5
Carbamide peroxide
• more than 9 per cent up to 60 per cent A,G3,E2,S1
• more than 60 per cent A,G1,G3,G4,E2,S1
Carbon disulfide A,G3,E2,R1,S2
Carbon tetrachloride A,G3,E1,R1,S1
Cassia oil A,G3
Chlorinating compounds, except when separately specified, containing
• above 4 per cent and below 10 per cent of available chlorine A,G3,E1,S1
• 10 per cent or more of available chlorine A,G3,E2,S1
• leave-on or wash-off preparations above 5 per cent E1
• other preparations above 5 per cent E1,S1
Sodium metabisulphite A, G3
Sodium nitrite
• when included in Schedule 7 A,G1,G3
• when included in Schedule 5 or 6 A,G3
Sodium percarbonate
• when included in Schedule 5 A,G3,S1
Sodium persulfate A,G3,E2
Sodium stannate A,E1
Sodium sulfide A,G3,E2,S1
Sodium trichloroacetate A
Strychnine A,G1,G2,G3,R2
Styrene A,G3,S1,E1
Sulcofuron A
Sulfamic acid A,G3,E2,S1
Sulfuric acid A,G3,E2,S1
Terpenes, chlorinated A,G3
Tetrachloroethane A,G3,E1,R1,S1
Tetrachloroethylene A,G3,E2,R1,S1
Thiourea A
Thujone A,G3
Thyme oil A,G3
ortho-Tolidine A
Toluene
• above 75 per cent A,G3,E1,R1,S1
• 75 per cent and below A,G3
• in pressurised spray packs A
Toluenediamine
• in hair dyes A,E1
• in other preparations A,G1,G3,E1,S1
Trichloroacetic acid A,G3,E2,S1
Trichloroacetic acid alkali salts A
1,1,1-Trichloroethane A,G3,E1,R1,S1
Trichloroethylene A,G3,E1,R1,S1
Trichloroisocyanuric acid A,G3,E1,S1
Triethanolamine A,G3,E1,S1
Triethyl phosphate A,E1
Trifluoromethanesulfonic acid A,G3,E2
Triisopropanolamine lauryl ether sulfate A,E1,S1
Turpentine (mineral) A,G3
Turpentine oil (vegetable) A,G3,E2
White spirit A,G3
Xylene
• above 75 per cent A,G3,E1,R1,S1
• 75 per cent and below A,G3
• in pressurised spray packs A,G6,E1,S1
Xylenols A,G3,E2,S3
• in pressurised spray packs A,E1
Zinc chloride A,G3,E2,S1
Zinc sulfate A,G3,E2,S1
APPENDIX F
WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS
(other than agricultural and veterinary chemicals (including pesticides) registered by the
Australian Pesticides and Veterinary Medicines Authority and medicines for human use
when compliant with the requirements of the Required Advisory Statements for Medicine Labels)
INTRODUCTION
Warning Statements and Safety Directions
It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.
Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.
The wording of warning statements and safety directions specified in this Appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:
1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. calls must be logged and submitted for incorporation into the official collection of poisoning data.
WARNING STATEMENTS
1. Highly corrosive.
2. Corrosive.
3. Corrosive liquid.
4. Strongly alkaline.
5. Irritant.
6. May cause cancer.
7. WARNING Causes birth defects.
8. WARNING May be fatal to children.
9. Can be fatal to children if sucked or swallowed.
10. May produce severe burns.
11. WARNING Vapour may be harmful.
12. Vapour is harmful to health on prolonged exposure.
13. May be fatal if inhaled, swallowed or absorbed through skin.
14. Dust will irritate and burn eyes, nose and skin.
15. Liquid will cause burns.
16. Forms dangerous gas near radiators or naked flames.
17. Contact with eyes even for short periods can cause blindness.
18. Product will irritate the eyes, nose, throat and skin.
19. WARNING Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.
20. May give off dangerous gas if mixed with other products.
21. WARNING This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
22. Highly reactive oxidising chlorine compound.
23. May cause fire or explosion.
24. For external washing only. Rinse skin thoroughly after use.
25. Do not use on broken skin. Wash hands thoroughly after use.
26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.
27. Not for therapeutic use.
28. (Over) (Repeated) exposure may cause sensitisation.
29. If congestion persists, consult your doctor or pharmacist.
30. WARNING Do not use on face or on anal or genital areas.
31. WARNING Do not use on face or on anal or genital areas except on doctor’s advice.
32. This preparation should be part of an overall treatment plan regularly assessed with your doctor.
33. Do not take for periods longer than four weeks except on medical advice.
34. WARNING This medication may be dangerous when used in large amounts or for a long time (period).
35. CAUTION This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.
or
CAUTION This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.
36. For use under medical supervision only.
37. Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.
38. CAUTION Do not use for children under 2 years old unless a doctor has told you to.
39. This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.
40. This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.
41. Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.
42. WARNING Overuse may stain the skin or mouth.
43. Use of this product is not necessary in areas supplied with fluoridated water.
44. WARNING May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.
45. WARNING If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.
46. WARNING Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).
47. WARNING This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
48. WARNING This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
49. WARNING Do not mix with other medication except on veterinarian’s advice.
50. Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.
Irritant to skin, eyes, mucous membranes and upper respiratory tract.
52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.
53. CAUTION (Name of substance) should not be used by pregnant women.
Seek medical advice before first course of treatment.
55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.
56. WARNING Can cause elevated blood pressure and interact adversely with other medication.
57. Not to be applied to infants under 12 months of age unless on doctor’s advice.
58. Highly reactive oxidising bromine and chlorine compound.
59. May cause allergy.
60. Do not mix with detergents or other chemicals.
61. WARNING Can react with other medicines. Ask your doctor or pharmacist before taking.
62. Do not use if pregnant.
63. See a doctor if you are pregnant or diabetic.
64. See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days.
65. If getting better, keep using for (Insert number of days as per approved Product Information ) days.
66. See a doctor if problem returns.
67. Do not use if pregnant or likely to become pregnant.
68. If symptoms persist beyond 5 days consult a doctor (or) (dentist).
69. If symptoms recur within two weeks of completing the course, consult a doctor.
70. Use only under medical supervision if you are taking other medicines.
71. Do not use during the last three months of pregnancy.
72. Do not use in the eyes.
73. Do not use for acne.
74. Do not use under waterproof bandages unless a doctor has told you to.
75. Do not use for more than 7 days unless a doctor has told you to.
76. Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment.
77. WARNING May cause birth defects.
78. Attacks skin and eyes.
79. Will irritate eyes.
80. (Intentionally blank)
81. (Intentionally blank)
82. (Intentionally blank)
83. This paint is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use on, in or around the home.
84. Breathing the vapour is dangerous.
Provide adequate ventilation during application.
Do not use in the presence of a naked flame.
Do not smoke.
85. This paint contains lead and is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use for painting any building or fixed structure.
Do not use where contact with food or drinking water is possible.
86. This tinter contains lead.
Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.
87. (Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.
88. This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.
89. Application to skin may increase sensitivity to sunlight.
90. This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.
91. CAUTION Total iodine intake may exceed recommended level when taking this preparation.
92. WARNING Contains iodine - do not take when pregnant except on physician’s advice.
93. Causes severe burns, which are not likely to be immediately painful or visible.
94. WARNING Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.
95. CAUTION Do not use for children under 12 years old unless a doctor has told you to.
96. CAUTION This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.
97. Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.
98. Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.
99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.
100. Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.
101. Don’t use [this product/name of the product]: If you have a stomach ulcer
In the last 3 months of pregnancy [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]
If you are allergic to (name of substance) or anti-inflammatory medicines.
102. Unless a doctor has told you to, don’t use [this prouct/name of the product]:
For more than a few days at a time
With other medicines containing aspirin or other anti-inflammatory medicines
If you have asthma
In children under 12 years of age
In children 12-16 years of age with or recovering from chicken pox, influenza or fever
If you are pregnant.
103. See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.]
104. Unless a doctor has told you to, don’t use [this product/name of the product]:
For more than a few days at a time
With other medicines containing (name of substance) or other anti-inflammatory medicines
If you have asthma
If you are pregnant [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea].
105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.
106. Contains formaldehyde.
SAFETY DIRECTIONS - GENERAL
To be grouped together and prefaced with the words “SAFETY DIRECTIONS” (see Part 2, Labels and Containers, subparagraph 7(n) to this Standard).
12. Do not allow product to come into contact with other chemicals, especially acids.
13. Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.
14. Do not allow to get damp.
15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.
16. Store and transport in an upright container.
17. Do not mix with other chemicals.
18. Do not mix with different types of chlorinating chemicals.
19. Use clean containers for dispensing.
20. Mix with water only.
21. Do not add water to product add product to water, but in case of fire drench with water.
22. In case of spillage flush with large quantities of water.
23. Keep away from heat, sparks and naked flames.
24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.
25. Avoid contact with food.
26. Avoid contact with clothing.
27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.
28. Do not mix with hot water.
29. Obtain a supply of calcium gluconate gel.
30. (Intentionally blank.)
31. Do not use on broken skin.
32. Do not use under occlusive dressing.
33. Mix strictly according to instructions.
34. May cause fire if it comes into contact with other chemicals, paper or other flammable materials.
35. Wash gloves thoroughly, immediately after use.
36. Protect cuticles with grease or oil.
PART 3
POISONS (other than agricultural and veterinary chemicals) TO BE LABELLED WITH WARNING STATEMENTS
OR SAFETY DIRECTIONS
(Where more than one statement or direction is required, they may be combined to form simple sentences where appropriate.)
WARNING SAFETY
POISON STATEMENTS DIRECTION
Acetic acid in concentrations of 80 per cent 2 1,4,8
or more except when in Schedule 2.
Acetic anhydride 2 1,4,8
Acetone in concentrations greater than 75 per cent. 1,4,8
Acitretin 7,62,76
Adapalene for topical use. 62,77
Alclometasone when included in Schedule 3. 38,72,73,74,75
Alkaline salts 4 1,4
Ambrisentan 7,62,76
Amines used as curing agentsfor epoxy resins. 1,3,4,5,8
Ammonia/ammonium hydroxide in concentrations 4 1,4,8
greater than 20 per cent ammonia except
in smelling salts.
Ammonium persulfate 5,21,25 1,5,23,33,34
Anhydrides, organic acid, for use as curing agents 1,3,4,5,8
for epoxy resins.
Aniline 13 1,4,8
Antihistamines not separately specified 39 or 40
in this Appendix except:
(a) dermal, ocular, parenteral and paediatric preparations;
(b) oral preparations of astemizole,
desloratadine, fexofenadine,
loratadine or terfenadine;
(c) nasal preparations of azelastine; or
(d) preparations for the treatment of animals.
Aromatic extract oils 1,3,4,5,6
Aspirin
(a) for inhibition of platelet aggregation. 36
(b) in sustained release preparations 36 containing 650 mg or more of aspirin.
(c) in other preparations. 101,102,103
Astemizole 61
Azadirachta indica (neem) including its extracts and derivatives when included in Schedule 6. 67
Azocyclotin 48
Benomyl 46
Benzene 12 1,4,9
1,2-Benzenediol (Catechol) 51,59 1,4,8
Benzoyl peroxide when included in Schedule 2. 55
Benzoyl peroxide when included in Schedule 5. 1,4,8
Bergamot oil 89
Beryllium 1,4,8
Bexarotene
(a) for human use. 7,62,76
Bifluorides (including ammonium, potassium and sodium salts)
(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35
Bithionol for the treatment of animals. 1,4,8
Boron trifluoride (including mixtures that
generate boron trifluoride)
(a) when included in Schedule 5. 2 1,4
Bosentan 7,62,76
Bromoform 1,4,8
2-Butoxy-2’-thiocyanodiethyl ether 1,4,8
2-Butoxyethanol and its acetates 1,4,8
Camphor
(a) in block, ball, disc, pellet or flake form, 9
enclosed in a device which, in normal use,
prevents removal or ingestion of its contents.
(b) in other forms. 9 1
Carbamide peroxide
(a) more than 9 per cent up to 30 per cent. 5 1
(b) more than 30 per cent up to 60 per cent. 5 2
(c) more than 60 per cent. 2 2,4
Carbon disulphide 12 1,4,8,9,23
Carbon tetrachloride 12 1,4,8,9
Cassia oil 4
Chlorinating compounds
(a) in household cleaning or bleaching 20
preparations.
(b) in preparations containing less than 11 1,4,10
10 per cent of available chlorine.
(c) in liquid preparations containing 3,18 1,4,6,8,10, 15,16,
10 per cent or more of available chlorine. 17,18, 19,20,22,26
(d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,
or more of available chlorine. 14,15,16,17, 18,
19,20,21, 22,26
(e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13, or more of available chlorine certified by a 14,15,16,17, relevant State or Territory authority as not 18,19,20,21, being a Dangerous Good of Class 5, 22,26 Division 5.1:Oxidising substances, as
specified in the Australian Code for the
Transport of Dangerous Goods by Road
and Rail.
(f) in compressed block or tablets containing 10,22,23 12,13,14,15, 10 per cent or more of available chlorine 17,18,19,21 except in preparations for use in toilet cisterns only, containing 15 g or less of
trichloroisocyanuric acid.
(g) in other compressed blocks or tablets 10,22 12,13,14,15,
containing 10 per cent or more of available 17,18,19,21
chlorine certified by a relevant State or
Territory authority as not being a Dangerous
Good of Class 5, Division 5.1: Oxidising
substances, as specified in the Australian
Code for the Transport of Dangerous Goods
by Road and Rail except in preparations for
use in toilet cisterns only, containing 15 g or
less of trichloroisocyanuric acid.
Chloroform when included in Schedule 6 1,4,8
alpha-Chlorohydrin 13,51 1,4,8,9
Chromates (including dichromates) of alkali metals or ammonia 1,4,8
Chromium trioxide 2,14,15,23 1,4,8,13
Cimetidine when included in Schedule 3 70,96
Cinnamon bark oil 4
Clobetasone when included in Schedule 3. 72,73,74,75,95
Clotrimazole in vaginal preparations when included 54,63,64,66